Personalized Medicine Study in Childhood Arthritis to Predict and Improve Biologic Therapy Outcomes

What this Trial Is About

Childhood arthritis is a long-lasting and disabling condition affecting children. New biologic therapies target key molecules causing inflammation and are used for treatment, but these treatments may have serious side effects like infections or cancer, and are costly. Researchers aim to develop tests that understand each childs arthritis biology to better predict when to start or stop biologic therapies for personalized care. This study is an observational research project collecting detailed clinical data, biologic samples, and patient-reported outcomes from children with juvenile idiopathic arthritis JIA. It includes four groups children suspected of JIA untreated except for NSAIDs, those starting or switching biologic therapies, those stopping or tapering biologics after inactive disease, and children with severe or genetically influenced arthritis. Data is securely stored and analyzed in near real-time using advanced cloud technology. Participants will be closely monitored up to 24 months to collect clinical, biologic, and socioeconomic data. The study evaluates disease course, treatment responses, and remission, aiming to create predictive tools for more effective and safe treatment strategies. Outcomes include clinical and biological data collection, assessment of therapy use and discontinuation effects, and socioeconomic impact related to treatment. The study is managed by The Hospital for Sick Children and involves ongoing data integration throughout the trial.

UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease